ArticleMedicine2020

A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations.

Si-Yeon Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.